The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 27, 2018

Filed:

Feb. 21, 2014
Applicants:

University of Rochester, Rochester, NY (US);

The Research Foundation for the State University of New York, Albany, NY (US);

Inventors:

Maiken Nedergaard, Webster, NY (US);

Jeffrey J. Iliff, Portland, OR (US);

Helene Benveniste, Northport, NY (US);

Rashid Deane, Rochester, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 51/04 (2006.01); A61K 49/00 (2006.01); A61K 31/41 (2006.01); A61K 38/10 (2006.01); A61B 5/055 (2006.01); A61B 5/00 (2006.01); G01N 33/68 (2006.01); A61K 31/4178 (2006.01); A61K 31/437 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 49/06 (2006.01); A61M 27/00 (2006.01); A61B 6/03 (2006.01);
U.S. Cl.
CPC ...
A61K 51/0491 (2013.01); A61B 5/055 (2013.01); A61B 5/4064 (2013.01); A61B 5/4082 (2013.01); A61K 31/41 (2013.01); A61K 31/4178 (2013.01); A61K 31/437 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 38/10 (2013.01); A61K 49/0032 (2013.01); A61K 49/0054 (2013.01); A61K 49/06 (2013.01); A61M 27/00 (2013.01); G01N 33/6896 (2013.01); A61B 6/037 (2013.01); A61B 2576/026 (2013.01); G01N 2800/2814 (2013.01); G01N 2800/50 (2013.01);
Abstract

Methods are provided for measuring glio-vascular pathway ('glymphatic system') function in the brain of a mammal which include performing imaging of the brain and measuring cerebrospinal fluid-interstitial fluid (CSF-ISF) exchange in the brain. The methods can be used to track the exchange between CSF and ISF compartments. An imaging agent is optionally administered intrathecally. The imaging agent can be a negative or positive (paramagnetic) contrast agent and dynamic or contrast-enhanced magnetic resonance imaging (MRI) of the brain can be performed. The imaging agent can be a positron-emitting radionuclide tracer and positron emission tomography (PET) can be performed. Methods for treating diseases or disorders of the mammalian brain are also provided, in which the methods increase or decrease glymphatic clearance.


Find Patent Forward Citations

Loading…